Author

A. O. Bueverov

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Metabolic-associated fatty liver disease and hypertriglyceridemia: cardiovascular risks and current therapeutic approaches

Metabolic-associated fatty liver disease (MAFLD) is a systemic disorder associ-ated with metabolic dysfunction and a high risk of life-threatening conditions, primarily cardiovascular disease. MAFLD is often accompanied by hypertriglyceridemia (HTG), as both conditions share a common pathogenetic mechanism — insulin re...

Y. Khalimov, M. Yezhov, K. Raikhelson et al. · Russian Journal of Cardiolog... · 0 citations

Open access Sep 2026

Efficacy and Safety of an 8-Week Antiviral Therapy for Chronic Hepatitis C with Ravidasvir and Sofosbuvir

Introduction. Hepatitis C virus (HCV) genotype 3 is associated with accelerated progression of liver disease; therefore, individuals infected with this genotype represent a clinically significant subgroup of patients. Despite the high efficacy of direct-acting antivirals, the optimal duration of therapy remains a su...

P. Bogomolov, A. O. Bueverov, N. Barsukova et al. · Russian Journal of Gastroent... · 0 citations

Review Open access Sep 2026

Fixed-Dose Combinations of Glycyrrhizic Acid + Phospholipids and Glycyrrhizic Acid + Ursodeoxycholic Acid in the Treatment of Non-Alcoholic Fatty Liver Disease (Literature Review and Expert Council Resolution)

Aim: to evaluate, based on an analysis of preclinical and clinical data, the efficacy and safety of fixed combinations of glycyrrhizic acid with phospholipids or ursodeoxycholic acid for the treatment of non-alcoholic fatty liver disease. Key points. Glycyrrhizic acid exerts antisteatotic, anti-inflammatory, and a...

S. Okovityi, K. Raikhelson, A. O. Bueverov et al. · Russian Journal of Gastroent... · 0 citations